DrugPatentWatch Database Preview
Drugs in Development Information for CUDC-907
» See Plans and Pricing
What is the development status for investigational drug CUDC-907?
CUDC-907 is an investigational drug.
There have been 13 clinical trials for CUDC-907.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 1st 2016.
The most common disease conditions in clinical trials are Lymphoma, Head and Neck Neoplasms, and Astrocytoma. The leading clinical trial sponsors are Curis, Inc., National Cancer Institute (NCI), and National Institutes of Health (NIH).
There are thirteen US patents protecting this investigational drug and one hundred and ten international patents.
Summary for CUDC-907
| US Patents | 13 |
| International Patents | 110 |
| US Patent Applications | 33 |
| WIPO Patent Applications | 389 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2016-12-01) |
| Vendors | 54 |
Recent Clinical Trials for CUDC-907
| Title | Sponsor | Phase |
|---|---|---|
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Cannonball Kids' Cancer Foundation | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Curis, Inc. | Early Phase 1 |
| Fimepinostat in Treating Brain Tumors in Children and Young Adults | Pacific Pediatric Neuro-Oncology Consortium | Early Phase 1 |
Clinical Trial Summary for CUDC-907
Top disease conditions for CUDC-907
Top clinical trial sponsors for CUDC-907
US Patents for CUDC-907
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof | RACE ONCOLOGY LTD. (Melbourne, AU) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| CUDC-907 | Start Trial | Phosphoinositide 3-kinase inhibitors with a zinc binding moiety | Curis, Inc. (Lexington, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for CUDC-907
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| CUDC-907 | Australia | AU2012236367 | 2031-04-01 | Start Trial |
| CUDC-907 | Brazil | BR112013025340 | 2031-04-01 | Start Trial |
| CUDC-907 | Canada | CA2830822 | 2031-04-01 | Start Trial |
| CUDC-907 | Chile | CL2013002823 | 2031-04-01 | Start Trial |
| CUDC-907 | China | CN103582483 | 2031-04-01 | Start Trial |
| CUDC-907 | China | CN105461736 | 2031-04-01 | Start Trial |
| CUDC-907 | Cyprus | CY1117785 | 2031-04-01 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
